Navigation Links
Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
Date:1/3/2008

CALGARY, Jan. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R).

The trial, which is being carried out at The Ohio State University Comprehensive Cancer Center, is expected to enroll up to 70 patients with metastatic ovarian, peritoneal or fallopian tube cancers.

These cancer indications were selected after comprehensive preclinical studies carried out by the NCI indicated the reovirus can kill ovarian cancer cells.

The American Cancer Society estimates that more than 22,000 women will be diagnosed with ovarian cancer in the U.S. in 2007, and more than 15,000 will die from it.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. NCI Phase I/II systemic and intraperitoneal administr
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., ... banking and therapeutics, announced today that StemCyte has become ... Indy car driven by James Jakes ... IndyCar 2013 season.   StemCyte, Inc. and Rahal ... of umbilical cord blood banking and its educational initiative ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 The New ... STEM industries, Black Data Processing Associates (BDPA), is hosting ... June 8, 2013. This all-day event will encourage students ... learn the ins and outs from many of the ... p.m. at the New Jersey Institute of Technology, the ...
(Date:5/23/2013)... SynCardia Systems, Inc. ( http://www.syncardia.com ), ... Canada and CE (Europe) approved Total Artificial Heart, announced ... boasts more than 380,000 visitors annually, is featuring the ... the Freedom® portable driver as part of its $3 ... of its kind. , “BodyWorks combines the latest ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... UPPSALA, Sweden, June 29 , ... Will Fund Gyros to Profitability , ... development, announces that it has raised SEK 80 million,(approximately euro ... Company,s leading shareholder. The new funds will enable Gyros to ...
... Kornberg Associates | Architects ( www.kornberg.com ) has ... new Cognitive & Neurobiological Imaging Center. Ken Kornberg, president ... with Stanford University since 1980 and has completed ... is the two-story, 32,000 square-foot office building for the Stanford ...
... ... elimination, exterior plastic trim and headlight restoration products to the Automotive, RV and Marine ... myriad of industries, to introduce these innovative and eco-friendly products to the pan-national marketplace. ... ...
Cached Biology Technology:Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 4Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 2MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air 3
(Date:5/24/2013)... largest and fastest growing open-access publishers, today announces the ... . , A broad scope journal covering all specialties, ... and interactive web platform for the research community to ... Frontiers, real-time and interactive peer-review enables fast, fair and ... an average of three months from submission to final ...
(Date:5/24/2013)... to combat metastatic cancer , Cancer cells spread ... immune system. Stimulation of the immune system can help ... that cause the immune system to ignore cancer cells. ... suppress the immune system response. In this issue of ... by Ronald Levy at Stanford University found that regulatory ...
(Date:5/24/2013)... spread and grow by avoiding detection and destruction by ... help to eliminate cancer cells; however, there are many ... cells. Regulatory T cells are immune cells that function ... of the Journal of Clinical Investigation , researchers ... regulatory T cells that infiltrate tumors express proteins that ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8
... reproductive apparatus of a model virus is bolstering the idea ... important human diseases such as AIDS, SARS and hepatitis C ... vulnerable to broad-spectrum antiviral agents. In a study published ... of Science Biology, a team of researchers from the Howard ...
... 2007 It,s not a good idea to put all your ... in the parched Sonoran desert of southern Arizona and northern Mexico, ... senita cactus -- both for its food and for a place ... moth, the only species that pollinates its flowers. Senita cacti and ...
... In some ways, certain tumors resemble bee colonies, says pathologist ... specific role, and just a fraction of the cells serve ... an unspecialized state and seed new tumors. These cells can ... bulk of the tumor. These queens are cancer ...
Cached Biology News:Features of replication suggest viruses have common themes, vulnerabilities 2Features of replication suggest viruses have common themes, vulnerabilities 3Which came first, the moth or the cactus? 2Which came first, the moth or the cactus? 3Newly created cancer stem cells could aid breast cancer research 2Newly created cancer stem cells could aid breast cancer research 3
... Osteoclast cells form from a hematopoietic stem ... attaching to the bone surface and lowering ... of around 4.5. The bone mineral is ... differentiation and function is controlled primarily by ...
... Receptor-gamma (PPAR) is a member of ... transcription factors that heterodimerize with retinoic ... in the regulation of glucose and ... class of anti-diabetic agents called thiazolidinediones ...
... Nucleic acid hybridization Preparation ... mg BSA, 50 mg ficoll ... with 5 ml of water ... for molecular biology Density: 1.00 ...
... ProteinChip Antibody Capture Kit ... and optimization steps typically ... interactions. This kit enables ... of multiple antigens based ...
Biology Products: